We are bringing curative living medicines to life to free patients from the siege of autoimmune disease.
Trailblazing Science Meets Unmet Patient Need
Smart Science, Smarter Medicines
Kyverna is developing living therapies with multiple immunosuppressive mechanisms to help restore balance to the immune system. Our approach leverages two platforms to target the underpinnings of autoimmunity: synReg-T cells (synthetic regulatory T cells) to suppress pathogenic immune cells in specific organs and tissues, and synNotch CAR-T cells (chimeric antigen receptor T cells) with dual receptor recognition logic to eliminate pathogenic immune cells. synNotch is an enabling T cell engineering technology licensed from Gilead/Kite.